Follow-On Biologics Bill Could Be Shaped By Waxman/Dingell Fight For House Commerce Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Chairmanship would give Waxman more leverage to place regulatory flexibility into the biosimilars approval pathway.
You may also be interested in...
NIH Grants Unlikely To Be In Recovery Bill, Pallone Says
Wish list for stimulus package gets airing at a hearing in Energy and Commerce’s Health Subcommittee, where Pallone and Dingell agree on priorities, though not leadership.
NIH Grants Unlikely To Be In Recovery Bill, Pallone Says
Wish list for stimulus package gets airing at a hearing in Energy and Commerce’s Health Subcommittee, where Pallone and Dingell agree on priorities, though not leadership.
Kennedy/Grassley Imports Criminal Liability To Global Drug Safety Efforts
A senior drug company officer or director would be required personally to certify the veracity of product applications and safety submissions to FDA, under Sens. Edward Kennedy, D-Mass., and Chuck Grassley's, R-Iowa, bill to improve safety in global drug manufacturing and distribution